Skip to main
RAPP

RAPP Stock Forecast & Price Target

RAPP Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions. With a strong portfolio from its RAP technology platform, including RAP-219 in pivotal trials for focal onset seizures and bipolar mania, the company has positioned itself as a potential leader in the treatment of these disorders. Additionally, RAP-219's differentiated mode of action and promising safety profile make it a strong potential contender in an already competitive market.

Bears say

Rapport Therapeutics is currently facing multiple risks that could hinder its success in the competitive epilepsy and bipolar disorder markets, including stiff competition from established players and the dependence on third-party suppliers for product manufacturing. Despite promising clinical results and a unique approach through RAP technology, there is no guarantee that Rapport's sales force will be able to gain a significant market share. The risks extend to regulatory, developmental, and commercial areas, making it a high-risk investment.

RAPP has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rapport Therapeutics Inc (RAPP) Forecast

Analysts have given RAPP a Buy based on their latest research and market trends.

According to 7 analysts, RAPP has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rapport Therapeutics Inc (RAPP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.